BiPAP A40 EFL Ventilator The first and only purpose-built COPD NIV therapy proven to screen, detect and abolish EFL

BiPAP A40 EFL Ventilator

The first and only purpose-built COPD NIV therapy proven to screen, detect and abolish EFL

Find similar products

While the majority of COPD patients have EFL, care teams have never had a COPD NIV ventilation therapy that dynamically and automatically targets EFL. BiPAP A40 EFL is the first and only NIV therapy precision-crafted to abolish EFL in hypercapnic COPD patients. It screens, detects and auto-optimizes pressure – to treat comfortably and redefine what is possible in managing COPD.

  • 1. Dellaca, R. L., Santus, P., Aliverti, A., Stevenson, N., Centanni, S., Macklem, P. T. & Calverley, P. M. A. (2004). Detection of expiratory flow limitation in COPD using the forced oscillation technique. European Respiratory Journal, 23(2), 232-240.
  • 2. Aarli, B. B., Calverley, P. M., Jensen, R. L., Dellacà, R., Eagan, T. M., Bakke, P. S., & Hardie, J. A. (2017). The association of tidal EFL with exercise performance, exacerbations, and death in COPD. International journal of chronic obstructive pulmonary disease, 12, 2179 † COPD patients with a DeltaXrs ≥ upper normal limit (ULN)
  • 3. ES Suh1, P. P. (2014). Abolition of expiratory flow limitation in severe COPD using auto-titrating CPAP based on the measurement of within-breath airway reactance determined by the forced oscillation technique. †† Context: Stable and Ventilated Hypercapnic COPD patients
  • 4. Key ventilation parameters, alarm data, device performance and patient usag